Pioneering
Hybrid DrugsTM
Redefining combination therapy by fusing traditional pharmaceuticals with clinically validated app-delivered protocols in a single, regulated prescription.
What are Hybrid DrugsTM?
Hy·brid Drugs: (plural noun)
Pharmaceutical molecules + personalized protocols = Better Results
Many medical conditions respond better to combining biological and behavioral therapy. Remepy’s clinically tested and validated Hybrid Drugs integrate traditional medication with innovative digital interventions that enhance motor, cognitive, and mental function - measurably improving outcomes, delivered via a personalized digital health app.
Regulated like medicine, adaptive like software, and reimbursed like pharma, Remepy’s Hybrid Drugs deliver superior outcomes while creating a new growth model for the entire industry.
HybridopaTM
The first Hybrid Drug for Parkinson’s Disease
Hybridopa, the world’s first hybrid drug for Parkinson’s Disease, pairs Levodopa with a digital protocol to improve motor, cognitive, mental and speech function.
Hybridopa, the pioneering Software as a Medical Device (SaMD) - Drug combination will enter phase 3 in H2 2026, following a successful double-blind placebo-controlled study.
Rooted in Deep Science
At Remepy, data, behavioral and neuroscience converge. Our digital protocols draw on validated interventions in speech, motor, cognitive, and emotional domains - each designed to modulate key biological mechanisms.
These mechanisms are translated into daily, adaptive protocols delivered through our app and paired with medication to amplify therapeutic outcomes. Learn more
Scientific Publications
Managing Disease at the Intersection of Biology, Behavior & Therapy
FAQs
Hybrid drugs are therapies that combine traditional medications with digital therapeutics. Remepy is a global leader in hybrid drug development, bringing this new treatment model to patients worldwide.
Traditional drugs act only on biological pathways. Remepy hybrid drugs add digital therapeutics that actively train the brain and body, delivering more comprehensive results.
Hybrid drugs, such as those developed by Remepy, represent the future of personalized care by uniting pharmaceuticals and digital health in one therapy.
Remepy designs its hybrid drugs according to PDURS standards, ensuring that both drug and digital components meet FDA requirements.
PDURS creates a clear regulatory framework for drug-software combinations. Remepy’s leadership in PDURS-aligned development positions it at the forefront of this innovation.
